NEW YORK (GenomeWeb) – ERS Genomics said today that it has signed a non-exclusive license agreement for its CRISPR-Cas9 patents with Charles River Laboratories.

Charles River, which uses CRISPR-Cas9 for target screening and to create custom knock-in and knockout cell lines for drug discovery applications, said it will use the license to offer its customers a larger range of in vivo and in vitro genome editing services.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.